MONTREAL and SMITHS FALLS, ON, Sept.
16, 2019 /CNW/ - Québec doctors have a new tool at
their disposal for learning about medical cannabis and its
viability as a treatment option for their patients.
Santé Cannabis, a pioneer in medical cannabis in Québec, has
partnered with Spectrum Therapeutics, the medical division of
Canopy Growth (TSX: WEED) (NYSE: CGC) to launch the Prescriber
Training Program, designed to aid physicians and patients,
announced today at the new Santé Cannabis clinic and research
centre in Montréal.
This new initiative developed by Santé Cannabis equips
physicians with the most up-to-date clinical guidelines, support
networks, online and in-person training opportunities so they can
prescribe and monitor cannabinoid treatment plans with confidence.
The program will be offered for free to Québec physicians and is
made possible by an unrestricted educational grant from Spectrum
Therapeutics.
"Patient referrals and training requests from our physician
colleagues have increased by more than 500 per cent over the last
year," says Dr. Michael Dworkind,
Medical Director of Santé Cannabis and McGill
University Associate Professor of Family Medicine. "It is
our duty as physicians to understand the available treatment
options for our patients, and medical cannabis treatments have
emerged as an important clinical tool. In this program, we extend
our experience and expertise to healthcare professionals, in order
to support them to meet the needs of their patients."
The Prescriber Training Program is designed by clinicians for
clinicians, and gives a unique, practical approach to medical
cannabis learning. It provides participating physicians with:
- Self-learning modules that detail treatment evidence for
specific conditions and symptoms;
- Ongoing personalized phone support for questions about medical
cannabis and patient care;
- Clinical preceptorship opportunities at four Santé Cannabis
locations across Québec;
- Practical reference guidebook on developing and managing
treatment plans and dosing; and
- Clinical toolkits to help navigate patient assessment and
follow-ups.
"A significant issue preventing the consideration of cannabinoid
medicine by healthcare professionals is that the topic is not
typically included in the medical school curriculum," comments Dr.
Mark Ware, Chief Medical Officer,
Canopy Growth. "We've invested in a range of training and education
initiatives to address this gap in knowledge, and this new program
creates an important resource for Québec physicians interested in
learning how to integrate medical cannabis into their
practice."
As Québec's first and foremost medical cannabis clinic and
research centre, Santé Cannabis has received referrals from more
than 2,500 physicians and assessed over 6,000 patients since 2014,
while also providing information sessions for patients and
healthcare professionals. Spectrum Therapeutics' track record with
providing industry-leading education, resources and support for
healthcare professionals includes:
- Evidence-based educational courses in Canada that have been delivered to thousands
of physicians, nurses, and pharmacists, including accredited
medical education programs through the Canadian Council on
Continuing Education in Pharmacy (CCCEP)
- A first-of-its-kind Catalyst Peer Mentorship Program, which
links physicians from across Canada with colleagues who possess advanced
knowledge of the cannabis field in order to provide case-by-case
support.
- 71,000+ interactions with healthcare professionals
Media are invited to attend an open house to learn more about
the program and visit the recently expanded Santé Cannabis clinic
and research centre in Montréal including a guided tour.
Santé Cannabis Medical Director Dr. Michael Dworkind, Practicing Physician Dr.
Alain Watier, and Canopy Growth
Chief Medical Officer, Dr. Mark Ware
will be available for interviews. Event details
below:
Date: Tuesday, September 17th
2019
Time: 9:00AM to 5:00PM
Address: 225-4150 Rue Sainte-Catherine Ouest, Westmount, H3Z 2Y5
RSVP: If you'd like to attend, please RSVP with Lilia Rassoul (media@santecannabis.ca)
ABOUT SANTÉ CANNABIS
Santé Cannabis is Québec's
leading specialized medical cannabis clinic and research centre,
with clinics operating in Montreal, Quebec
City, Sherbrooke and
Pointe Claire. Santé Cannabis
is a trusted and essential consultative service for over 2500
physicians who have referred more than 12,000 patients since
2014. The clinical care team is comprised of family physicians
and specialists in chronic pain, cancer, gastroenterology, and
endocrinology, as well as nurses with clinical expertise in
cannabis medicine. Santé Cannabis provides online and onsite
training for healthcare professionals, researchers, and decision
makers from all over the world. As a Contract Research Organization
specialized in medical cannabis, Santé Cannabis offers
consultation, data management and clinical trial services to a
diverse range of clients from pharmaceutical, biotech and cannabis
industries.
ABOUT SPECTRUM THERAPEUTICS
Spectrum Therapeutics, the
medical division of Canopy Growth Corporation (TSX: WEED, NYSE:
CGC), is dedicated to educating healthcare practitioners,
furthering the public's understanding of medical cannabis and its
various applications, and cutting edge, commercializable research
and IP development. Founded in Canada, Spectrum Therapeutics operates in
Australia, South America, Africa and across Europe. Its products are available in a wide
range of potencies and formats designed to simplify the dialogue
around strength and dosage by applying a colour-coded spectrum to
categorize medical cannabis according to THC and CBD levels.
Spectrum Therapeutics' offerings include whole flower cannabis,
oils and new innovations such as Softgels in addition to single
cannabinoid medicine Dronabinol under the brand Bionorica Ethics.
Through product simplification, robust clinical research and
ongoing education of healthcare professionals, Spectrum
Therapeutics is committed to addressing the unmet medical needs of
patients around the globe.
About Canopy Growth Corporation
Canopy Growth
(TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp
and cannabis device company, offering distinct brands and curated
cannabis varieties in dried, oil and Softgel capsule forms, as well
as medical devices through the Company's subsidiary, Storz &
Bickel GMbH & Co. KG. From product and process innovation to
market execution, Canopy Growth is driven by a passion for
leadership and a commitment to building a world-class cannabis
company one product, site and country at a time. The Company has
operations in over a dozen countries across five continents. The
Company's medical division, Spectrum Therapeutics is proudly
dedicated to educating healthcare practitioners, conducting robust
clinical research, and furthering the public's understanding of
cannabis, and has devoted millions of dollars toward cutting edge,
commercializable research and IP development. Spectrum Therapeutics
sells a range of full-spectrum products using its colour-coded
classification Spectrum system as well as single cannabinoid
Dronabinol under the brand Bionorica Ethics. The Company operates
retail stores across Canada under
its award-winning Tweed and Tokyo Smoke banners. Tweed is a
globally recognized cannabis brand which has built a large and
loyal following by focusing on quality products and meaningful
customer relationships. From our historic public listing on the
Toronto Stock Exchange and New York Stock Exchange to our continued
international expansion, pride in advancing shareholder value
through leadership is engrained in all we do at Canopy Growth.
Canopy Growth has established partnerships with leading sector
names including cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and
Green House Seeds, and Fortune 500 alcohol leader Constellation
Brands, to name but a few. Canopy Growth operates eleven licensed
cannabis production sites with over 4.7 million square feet of
production capacity, including over one million square feet of GMP
certified production space. For more information visit
www.canopygrowth.com
Notice Regarding Forward Looking Statements
This news
release contains "forward-looking statements" within the meaning of
the United States Private Securities Litigation Reform Act of 1995
and "forward-looking information" within the meaning of applicable
Canadian securities legislation. Often, but not always,
forward-looking statements and information can be identified by the
use of words such as "plans", "expects" or "does not expect", "is
expected", "estimates", "intends", "anticipates" or "does not
anticipate", or "believes", or variations of such words and phrases
or state that certain actions, events or results "may", "could",
"would", "might" or "will" be taken, occur or be achieved.
Forward-looking statements or information involve known and unknown
risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Canopy Growth or its
subsidiaries to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements or information contained in this news
release. Examples of such statements include "most up-to-date
clinical guidelines, support networks, online and in-person
training opportunities", and "will be offered for free". Risks,
uncertainties and other factors involved with forward-looking
information could cause actual events, results, performance,
prospects and opportunities to differ materially from those
expressed or implied by such forward-looking information, including
medical cannabis regulations and such risks contained in the
Company's annual information form dated June
24, 2019 and filed with Canadian securities regulators
available on the Company's issuer profile on SEDAR at
www.sedar.com. Although the Company believes that the assumptions
and factors used in preparing the forward-looking information or
forward-looking statements in this news release are reasonable,
undue reliance should not be placed on such information and no
assurance can be given that such events will occur in the disclosed
time frames or at all. The forward-looking information and
forward-looking statements included in this news release are made
as of the date of this news release and the Company does not
undertake an obligation to publicly update such forward-looking
information or forward-looking information to reflect new
information, subsequent events or otherwise unless required by
applicable securities laws.
SOURCE Canopy Growth Corporation